Key Points
- Daniel Asher, a major shareholder, bought 15,540 Ekso Bionics shares on Feb. 19 at an average price of $12.30 for $191,142, raising his stake to 270,432 shares (about $3.33M), a 6.10% increase in ownership.
- Ekso Bionics shares fell about 9.1% to open at $11.18, with a market cap near $29.3M, 50-day/200-day moving averages of $8.30/$5.75, and a one‑year range of $2.73–$13.27.
- Analyst and institutional activity is mixed—one Buy, one Hold and one Sell produce an average Hold rating with a $10.50 price target, while firms like Geode and Citadel have recently added or initiated positions.
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO - Get Free Report) major shareholder Daniel Asher acquired 15,540 shares of the stock in a transaction on Thursday, February 19th. The shares were acquired at an average price of $12.30 per share, with a total value of $191,142.00. Following the purchase, the insider owned 270,432 shares in the company, valued at $3,326,313.60. This represents a 6.10% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Ekso Bionics Trading Down 9.1%
Shares of EKSO stock opened at $11.18 on Friday. The stock has a fifty day moving average of $8.30 and a two-hundred day moving average of $5.75. The firm has a market capitalization of $29.33 million, a PE ratio of -1.97 and a beta of 0.80. Ekso Bionics Holdings, Inc. has a 1 year low of $2.73 and a 1 year high of $13.27. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.09 and a current ratio of 1.66.
Institutional Investors Weigh In On Ekso Bionics
Several institutional investors and hedge funds have recently added to or reduced their stakes in EKSO. Geode Capital Management LLC lifted its holdings in Ekso Bionics by 68.9% during the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company's stock valued at $218,000 after purchasing an additional 10,281 shares during the last quarter. Citadel Advisors LLC bought a new position in Ekso Bionics in the third quarter worth $198,000. Shay Capital LLC purchased a new stake in shares of Ekso Bionics in the 3rd quarter worth approximately $67,000. Virtu Financial LLC bought a new stake in Ekso Bionics in the 3rd quarter worth approximately $57,000. Finally, Consolidated Portfolio Review Corp purchased a new stake in Ekso Bionics in the third quarter worth about $333,000. Hedge funds and other institutional investors own 6.42% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on EKSO. Weiss Ratings reissued a "sell (e+)" rating on shares of Ekso Bionics in a research report on Monday, December 22nd. HC Wainwright lowered shares of Ekso Bionics from a "buy" rating to a "neutral" rating in a report on Wednesday, December 31st. Finally, Wall Street Zen raised shares of Ekso Bionics to a "hold" rating in a research note on Saturday, December 13th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $10.50.
View Our Latest Stock Analysis on Ekso Bionics
About Ekso Bionics
(
Get Free Report)
Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.
In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
